MA-EXAGRID
ExaGrid ® today announced that CloudComputing.pt , Portugal’s premier enterprise cloud computing strategy provider, led Lusitania Seguros to install ExaGrid’s Tiered Backup Storage solution, which bolstered the insurance company’s data protection by increasing the capacity and variety of its data backups.
Lusitania emerged in the insurance market in 1986 as the first Insurance Company with 100% Portuguese capital. Since then, and over more than 30 years, it has always designed itself as a company with an eye on the future. A reliable partner in all situations, focusing on creating value for the national economy, in order to contribute decisively to the progress and well-being of the entire Portuguese society.
The IT staff at Lusitania had modernized its infrastructure and used Veeam to back up its VMware environment, but needed to add to that as the company’s data and backup needs grew. “We wanted to expand our Veeam solution and we also needed to back up more Oracle databases and file servers, but we didn’t have enough time in our backup window to add more backup jobs,” said Miguel Rodelo, senior systems engineer at Lusitania. “We decided to test new solutions, and started to request proofs of concept (POC) for different products.”
Rodelo and his enterprise IT provider, David Domingos, chief sales officer at CloudComputing.pt, had attended VMWorld 2018 in Barcelona, where they stopped by the ExaGrid booth at the conference to learn more about the tiered backup storage solution, and ended up requesting a POC. “We decided together to bet on the ExaGrid technology,” said Rodelo. “I said that if the technology is as good as it claims to be I will buy it, and my reseller said that if it was that good, he would tell every client in Portugal about it.
“ExaGrid was the last POC that we were analyzing, and it ended up being the fastest and easiest to implement, and compared to the other products we were looking into at the same time, it was clear that ExaGrid offered the best backup performance, especially when it came to our Oracle data. I expected ExaGrid to integrate well with Veeam, and it did, but when I saw that I can also use Oracle RMAN to make direct backups to ExaGrid, I decided to implement ExaGrid as our central data storage for backups,” said Rodelo.
After working with ExaGrid to deliver high-performance backup storage to his client at Lusitania, David Domingos is eager to recommend the tiered backup storage solution to more CloudComputing.pt clients. “One of the best features of the ExaGrid system is that the client doesn’t feel the impact of data deduplication because of the Landing Zone feature. When you look at traditional storage, you run into capacity issues, but ExaGrid’s deduplication resolves those issues. In addition, ExaGrid speaks all of the languages of the backup apps and software, so if a client is using multiple approaches, such as Veeam and Oracle RMAN, or even Commvault or Veritas, ExaGrid will support all of them. ExaGrid is versatile and that adds to the value it brings our clients.”
ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups so that an RTO and RPO can be easily met. Available system cycles are utilized to perform deduplication and offsite replication for an optimal recovery point at the disaster recovery site. Once complete, the onsite data is protected and immediately available in its full undeduplicated form for fast restores, VM Instant Recoveries, and tape copies while the offsite data is ready for disaster recovery.
Read the complete Success Story to learn more about Rodelo’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.
About CloudComputing.pt
CloudComputing.pt was founded in 2010 with the objective to provide services to the corporate market based on Cloud Computing, Mobility and Information Security. The motivation to work in these fields is based on the strategic view that the organization's efficiency is measured by the capacity to share business information in real time with the right people in a safe manner anywhere. This way we promote clients' continuous innovation and value, based on the following skills: UEM Security, Identity and Access Management, Cloud and On-Premise Security and Infrastructure.
About ExaGrid
ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories .
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom